Cytomegalovirus (CMV) polyradiculopathy presenting as a cauda equina syndrome is now a well described disorder in AIDS and is estimated to occur in 2% ofAIDS patients with neurological problems.' Although dihydroxypropoxymethylguanine (DHPG, ganciclovir) has been shown to be effective, the optimum dose and duration of induction therapy have not been determined. Trisodium phosphonoformate guanine (foscarnet) The first signs of improvement were noted after two weeks of treatment with foscarnet.
Over the next five weeks clinical improvement continued. However, owing to deteriorating renal function after 7 weeks of treatment with foscarnet, ganciclovir at a reduced maintenance dose of 3 mg/kg/day (5 out of 7 days) was reinstituted. This has continued to be self administered at home via a Hickman line. Zidovudine had been discontinued 4 weeks after it was restarted because of anaemia.
Five months after the initial presentation, the patient is mobile around his home using crutches but still requires an indwelling urinary catheter. The most prominent deficit is a left foot drop and absent ankle reflexes.
We report this case to highlight four issues regarding treatment of CMV polyradiculopathy in AIDS patients: firstly, substantial improvement is possible in this condition. Our patient improved from having a complete flaccid paralysis to being mobile with crutches. Secondly, unless the patient's general condition dictates otherwise, a deterioration in spite of treatment should not be a deterrent to the continuation of anti CMV therapy. With regards to drug dosages and the necessity for maintenance treatment, much of the experience from CMV retinitis has been extrapolated to CMV polyradiculopathy. A review of the literature shows that induction therapies of ganciclovir 5-10 mg/kg/day for between 10 to 21 days are being used. This case suggests that high dose induction therapy of anti-CMV treatment should be continued at least until there is no further neurological improvement. Finally, although it is difficult to attribute improvement in our patient specifically to foscarnet, this may be an effective alternative to ganciclovir in CMV polyradiculopathy as in, for example, CMV retinitis. Furthermore, as foscarent is less myelotoxic than ganciclovir, zidovudine therapy may be continued. Foscarent should be considered as alternative therapy in cases where no improvement has occurred after two to three weeks of treatment with ganciclovir or in cases intolerant of ganciclovir. Clearly, further studies comparing the efficacy of these two therapies are required. (table) . Although gonorrhoea has previously been reported,' 2 and still continues, to be the commonest STD in Zambia, it is pertinent to note that following the exponential upsurge in cases of chancroid and syphilis in 1987,' the incidence of genital ulceration has outstripped that of genital discharge/urethritis: genital ulcers accounted for 59% of 10,089 new cases of STD at the University Teaching Hospital, Lusaka, in 1989; and the annual cases of chancroid and syphilis combined, which previously were much less than gonorrhoea, have since surpassed those of gonorrhoea. As genital ulceration has been shown to be a risk factor for transmission' and acquisition of HIV,3 4 the relative rise in genital ulceration is a cause for concern. Further work is required in order to elucidate factors underlying these trends.
In view of epidemiologic similarities between conventional STDs and HIV infection, the high incidence of STDs is an indicator of continued sexual transmission of HIV. And given the high prevalence of HIV among STD patients56 and the impact of concomitant HIV infection on conventional STDs,7 the current STD trends have serious implications for both the STD and AIDS control programmes.
Sexually transmitted infections in selected high risk populations in Cameroon
The renewed interest in sexually transmitted diseases (STDs) lies both in their increasing incidence and morbidity associated with them, as well as the fact that they enhance transmission of the human immunodeficiency virus (HIV).`4
We wanted to study the prevalence of Chlamydia trachomatis, Neisseria gonorrhoea, syphilis and HIV infections in parturients, pregnant women and STD clinic attenders in Cameroon in order to develop a targetted STD/HIV intervention programme.
The study was carried out from March to May 1990, and August to October 1990. Cervical specimens were taken from 69 randomly selected parturients in the Laquintinie Hospital, Douala. We also recruited 192 patients (101 female and 91 male) from the STD clinic in Elig-Essono, Yaounde. Urethral samples were obtained and stored using the appropriate swabs and media (Abbott Laboratories, Wiesbaden, Germany). We tested 135 STD patients for Chlamydia trachomatis infection (69 men and 66 women), 120 (66 women and 54 men) for Neisseria gonorrhoea while only (47 women and 46 men) agreed to HIV testing.
In addition, 350 pregnant women attending the central antenatal clinic in Yaounde were recruited. The 192 STD patients and the 350 pregnant women were tested for antibodies to Treponema pallidum.
Chlamydia and gonorrhoea antigen detection were performed with commercial enzymeimmunoassays (Chlamydiazyme and Gonozyme from Abbott Laboratories, Wiesbaden). Anti-HIV antibody screening was performed with the Abbott recombinant HIV-1/2 enzyme immuno-assay. Positive samples were confirmed on line immuno assay and HIV-1 western blotting (Organon Teknika, Teknika, Turnhout, Belgium). Syphilis testing was done by the haemagglutination test (TPHA) obtained from Behring, Marburg, Germany (Cellognost Syphilis H).
The results obtained are shown in the table. Sex prevalence among the STD patients for
